Publikationen, an denen er mitarbeitet Oreste Gualillo (3)

2023

  1. The lipidomic and inflammatory profiles of visceral and subcutaneous adipose tissues are distinctly regulated by the SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats

    Biomedicine and Pharmacotherapy, Vol. 161

2022

  1. The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile

    Frontiers in Pharmacology, Vol. 13

2021

  1. Relaxin has beneficial effects on liver lipidome and metabolic enzymes

    FASEB Journal, Vol. 35, Núm. 7